# Meriel Owen

> Meriel Owen is a Series B investor at Alzheimer's Drug Discovery Foundation backing Health Care. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Alzheimer's Drug Discovery Foundation](https://shizune.co/investors/profile/alzheimers-drug-discovery-foundation)
- Location: San Francisco Bay Area, United States
- Total investments: 1
- Last investment: Aug 2024
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/meriel-owen-04540824/

Meriel Owen is a Series B investor at Alzheimer's Drug Discovery Foundation in San Francisco Bay Area focused on Health Care and Neuroscience. Meriel Owen

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 1 | 100% |
| Neuroscience | 1 | 100% |
| Therapeutics | 1 | 100% |
| Pharmaceutical | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Neuro Therapia | NeuroTherpia, Inc., founded in 2015 by Drs. Mohamed Naguib and Joseph Foss, is developing new therapies for diseases with an underlying component of neuroinflammation. Initial research has led to the development of our lead compound NTRX-07. NTRX-07 (previously known as MDA7) has been shown to decrease activation of microglial cells in the brain.Decreasing activation of these cells leads to decreased inflammation and decreased injury to surrounding nerve cells. Decreasing this inflammation can treat and even prevent the development of neuropathic pain in settings of nerve injury or chemotherapy. Recent work has shown that blocking this inflammation is also important in reversing the effects seen in Alzheimer's disease. We are currently doing preclinical safety studies and plan on studying NTRX-07 in humans in 2016. | $12.3M | Series B | Aug 06, 2024 |  |

1 of 1 investments shown.

## Co-investors
- [Cleveland Clinic](https://shizune.co/investors/profile/cleveland-clinic) — VC Fund, 2 deals together
- [Brain Trust Accelerator Fund](https://shizune.co/investors/profile/brain-trust-accelerator-fund) — VC Fund, 1 deal together
- [CRUINT](https://shizune.co/investors/profile/cru-hungary) — VC Fund, 1 deal together
- [Dolby Family Ventures](https://shizune.co/investors/profile/dolby-family-ventures) — VC Fund, 1 deal together
- [Foundation for a Better World](https://shizune.co/investors/profile/foundation-for-a-better-world) — VC Fund, 1 deal together

## About Alzheimer's Drug Discovery Foundation

VC Fund · New York, United States

The Alzheimer’s Drug Discovery Foundation (ADDF) is the only public charity solely dedicated to finding effective drugs for Alzheimer’s disease. Our pioneering biomedical venture philanthropy approach allows us to invest in the most promising drug discovery and development programs around the world in both academic institutions andbiopharmaceutical companies. Since our founding in 1998, the ADDF has invested nearly $100 million to support over 500 programs across 18 countries.

5 contacts available at Alzheimer's Drug Discovery Foundation.

| Name | Title | Profile |
| --- | --- | --- |
| Howard Fillit | Co-Founder and Chief Science Officer | https://shizune.co/investors/profile/howard-fillit |
| Leonard Lauder | Co-Chairman & Co-Founder | https://shizune.co/investors/profile/leonard-lauder |
| Martin Tolar | Business Advisory Board & Scientific Review Board | https://shizune.co/investors/profile/martin-tolar |
| Meriel Owen | Director | https://shizune.co/investors/profile/meriel-owen-dfd5 |
| Ronald S. Lauder | Co-Chairman and Co-Founder | https://shizune.co/investors/profile/ronald-s-lauder |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Meriel Owen invest in?

Meriel Owen invests primarily in Health Care, Neuroscience and Therapeutics startups, most often at Series B stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Meriel Owen last invest?

The most recent investment recorded for Meriel Owen closed in Aug 2024. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co